|Awarded On||February 19, 2020|
|Title||Developing a First- in-Class BCL-XL Proteolysis Targeting Chimera (BCL- PROTAC) for Cancer Therapy|
|Program||Product Development Research|
|Award Mechanism||Seed Awards for Product Development Research|
|Institution/Organization||Dialectic Therapeutics, Inc.|
|Principal Investigator/Program Director||Joshua Sills|
|Cancer Sites||Leukemia, Lung and Bronchus, Lymphoma|
Dialectic Therapeutics (DT) is a biotech start up dedicated to the development of impactful and unique anti-cancer drugs to effectively treat cancers with few to no other options. Founded by three respected cancer scientists and two successful biotech investors, DT is located in Dallas and has research facilities/partners at UT Health in San Antonio (UTHSA) and the University of Florida. DT’s lead candidate, DT2216, is a unique compound called a BCL-XL proteolysis targeting chimera (PROTAC) that selectively induces cancer cells to degrade BCL-XL, stimulating the cells to commit suicide on its own, or become more susceptible to chemotherapy. Cancer cells are less likely to develop resistance ...